117 related articles for article (PubMed ID: 35636394)
21. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
Engvall K; Gréen H; Fredrikson M; Lagerlund M; Lewin F; Åvall-Lundqvist E
Breast Cancer Res Treat; 2022 Oct; 195(3):379-391. PubMed ID: 35941422
[TBL] [Abstract][Full Text] [Related]
22. A Randomized, Placebo-Controlled Trial Evaluating Changes in Peripheral Neuropathy and Quality of Life by Using Low-Frequency Electrostimulation on Breast Cancer Patients Treated With Chemotherapy.
Song SY; Park JH; Lee JS; Kim JR; Sohn EH; Jung MS; Yoo HS
Integr Cancer Ther; 2020; 19():1534735420925519. PubMed ID: 32493088
[No Abstract] [Full Text] [Related]
23. Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.
Zhi WI; Baser RE; Kwon A; Chen C; Li SQ; Piulson L; Seluzicki C; Panageas KS; Harte SE; Mao JJ; Bao T
Breast Cancer Res Treat; 2021 Apr; 186(3):761-768. PubMed ID: 33507480
[TBL] [Abstract][Full Text] [Related]
24. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.
Gewandter JS; Chaudari J; Ibegbu C; Kitt R; Serventi J; Burke J; Culakova E; Kolb N; Sluka KA; Tejani MA; Mohile NA
Support Care Cancer; 2019 May; 27(5):1765-1774. PubMed ID: 30151681
[TBL] [Abstract][Full Text] [Related]
25. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
[TBL] [Abstract][Full Text] [Related]
26. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
27. Exploring Patients' Understanding of Chemotherapy-Induced Peripheral Neuropathy.
Knoerl R; Berry DL; Meyerhardt J; Reyes K; Salehi E; Gewandter JS
J Cancer Educ; 2023 Jun; 38(3):906-912. PubMed ID: 35927535
[TBL] [Abstract][Full Text] [Related]
28. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
30. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
[TBL] [Abstract][Full Text] [Related]
31. Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer.
Ben-Horin I; Kahan P; Ryvo L; Inbar M; Lev-Ari S; Geva R
Integr Cancer Ther; 2017 Sep; 16(3):258-262. PubMed ID: 28150504
[TBL] [Abstract][Full Text] [Related]
32. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).
Joy L; Jolien R; Marithé C; Stijn E; Laura S; Hilde L; Sandra B; Wendy N; Ruth H; Liesbeth R; Sylvana S; Sylvia H; Jeroen M
Support Care Cancer; 2022 Jun; 30(6):5509-5517. PubMed ID: 35312857
[TBL] [Abstract][Full Text] [Related]
33. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
[TBL] [Abstract][Full Text] [Related]
34. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
35. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
38. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients.
Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D
Clin Auton Res; 2022 Dec; 32(6):497-506. PubMed ID: 36129622
[TBL] [Abstract][Full Text] [Related]
39. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
van Haren F; van den Heuvel S; Ligtenberg M; Vissers K; Steegers M
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1577. PubMed ID: 34687287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
